Riskpilot← Back to searchSign inGet full accessBBT Injekteringsteknik AB
ABActiveOrg 5566885801Munters Väg 9Other specialised construction activities n.e.c. · NACE 4399Est. 200516 employees
Revenue 2025
SEK 26,4M
+11% vs 2024
EBITDA margin
28.2%
+51% vs 2024
Equity ratio
35.5%
Financial strength
Net profit 2025
SEK 4,2M
+50% vs 2024
| Revenue | SEK 26,4M | +11% |
| EBITDA | SEK 7,4M | +51% |
| Net profit | SEK 4,2M | +50% |
| Total assets | SEK 15,2M | +35% |
| Equity | SEK 5,4M | +35% |
| Employees | 16 | — |
Legal name
BBT Injekteringsteknik AB
Org number
5566885801
Legal form
Aktiebolag
NACE code
4399 · Other specialised construction activities n.e.c.
Founded
24 oktober 2005
Share capital
SEK 133 300
Employees
16 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva tätning inom berg och betong.
Address
Munters Väg 9
Email
anders.bbt@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | — | 6 820 | 23 857 | 26 399 |
| Staff expenses | — | — | −2 009 | −9 118 | −10 049 |
| EBITDA | — | −10 | 3 297 | 4 924 | 7 444 |
| Depreciation & amort. | −0 | — | −131 | −286 | −612 |
| EBIT | 0 | −10 | 3 166 | 4 638 | 6 832 |
| Net financials | — | — | 3 | 109 | 145 |
| Profit before tax | 19 | 10 | 2 449 | 3 543 | 5 330 |
| Tax | −4 | −2 | −507 | −743 | −1 124 |
| Net profit | 15 | 8 | 1 942 | 2 800 | 4 207 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 451 | 378 | 5 301 | 11 288 | 15 232 |
| Equity | 250 | 258 | 2 200 | 4 000 | 5 407 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 101 | 40 | 2 301 | 5 284 | 6 175 |
| Total debt | 101 | 40 | 2 301 | 5 284 | 6 175 |
EBITDA margin
28.2%
This company
15.8%
Market median
+78% vs market
20212025
Equity ratio
35.5%
This company
38.2%
Market median
+7% vs market
20212025
Return on equity
77.8%
This company
18.4%
Market median
+323% vs market
20212025
Net profit margin
15.9%
This company
8.1%
Market median
+96% vs market
20212025
Asset turnover
1.73×
This company
1.12×
Market median
+54% vs market
20212025
Debt / equity
1.82×
This company
0.62×
Market median
-194% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CK Audit | Audit | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Sublimis Invest AB
BBT Injekteringsteknik AB Board members of BBT Injekteringsteknik AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Kristian Thore | Audit | 0 companies |
| Anders Nygren | Board of Directors | 0 companies |
| Urzula Elin V Martinsdotter Nygren | Deputy Board Member | 0 companies |